Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 162 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergens Clear all
Completed Phase 2 Interventional Results available

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

NCT02978183
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Early Phase 1 Interventional Results available

Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever

NCT01500629
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
C-1266-7, C-1266-6 (placebo)
Device
Lead sponsor
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 1 Interventional

Cockroach Allergen Reduction by Extermination Alone in Low-Income, Urban Homes: A Randomized Control Trial

NCT00341445
View directory record Official record
Conditions
Allergens
Interventions
Effect of Cockroach Allergen
Behavioral
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 2 Interventional

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

NCT01639846
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
RX-10045, Vehicle for RX-10045 arm
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 4 Interventional

Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen

NCT00638118
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
15 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Introduction and Maintenance of Still Eating Protein Blends in Support of Infant Nutritional Goals

NCT03667118
View directory record Official record
Conditions
Food Allergy
Interventions
Food Supplement
Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
5 Months to 11 Months
Enrollment
705 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Not applicable Interventional

Anxiety About Casual Exposure to Food Allergens

NCT03349047
View directory record Official record
Conditions
Food Allergy
Interventions
Behavioral intervention group, Education
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
108 Months to 210 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

Clinical Evaluation of Metal Panel Allergens: Dose Response Study

NCT02615249
View directory record Official record
Conditions
Dermatitis, Eczematous
Interventions
Metal Allergen Epicutaneous Patch
Biological
Lead sponsor
Allerderm
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 4 Interventional Results available

Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

NCT00517634
View directory record Official record
Conditions
Asthma
Interventions
FP, SFC, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

NCT02198664
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 - Peanut protein capsule
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics

NCT02230189
View directory record Official record
Conditions
Asthma
Interventions
Segmental airway allergen challenge, Bronchoscopy, Methacholine challenge test, Spirometry, Allergen skin prick test
Biological · Procedure · Diagnostic Test
Lead sponsor
Prescott Woodruff
Other
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Oct 24, 2026, 2:47 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

NCT07059091
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

NCT00562120
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, Allegra, Allegra-D, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
19 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 24, 2026, 2:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

NCT02243189
View directory record Official record
Conditions
Healthy, Asthma
Interventions
JNJ-43260295, Placebo, Nasal Allergen Challenge
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 1 Interventional

A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.

NCT01064726
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Ibuprofen, Fluticasone propionate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Oct 24, 2026, 2:47 PM EDT
Terminated Phase 2 Interventional

Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

NCT00318747
View directory record Official record
Conditions
Asthma, Allergy, Allergic Rhinitis, Rhinitis, Allergic, Seasonal
Interventions
Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 4 Interventional Results available

Assessment of Alcon's Ocular Image Quantification System

NCT01282138
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

NCT01904604
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
Interventions
Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

NCT01987817
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules, Placebo powder provided in capsules
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 24, 2026, 2:47 PM EDT
Completed No phase listed Observational

Evaluation of the Causes and Disease Processes of Chronic Lung Disease

NCT00001183
View directory record Official record
Conditions
Pulmonary Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
7 Years to 90 Years
Enrollment
6,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1984 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 24, 2026, 2:47 PM EDT
Not listed Phase 2 Interventional

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06153342
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 4 Interventional

Xolair in Patients With Chronic Sinusitis

NCT00117611
View directory record Official record
Conditions
Sinusitis
Interventions
Anti-IgE antibody omalizumab or placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 24, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

NCT00929968
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, VAK694, Fluticasone
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 24, 2026, 2:47 PM EDT
Active, not recruiting Early Phase 1 Interventional

Vaginal Microbiome Exposure and Immune Responses in C-section Infants

NCT03567707
View directory record Official record
Conditions
Allergic Diseases, Asthma
Interventions
Vaginal seeding, Placebo Seeding, Standard care, Post-seeding Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 24, 2026, 2:47 PM EDT